Since mould-active azole prophylaxis has become a standard approach for patients with high-risk haematologic diseases, the epidemiology of invasive fungal infections (IFIs) has shifted towards non-Aspergillus moulds. It was aimed to identify the epidemiology and characteristics of non-Aspergillus invasive mould infections (NAIMIs).
Summary
Since mould-active azole prophylaxis has become a standard approach for patients with high-risk haematologic diseases, the epidemiology of invasive fungal infections (IFIs) has shifted towards non-Aspergillus moulds. It was aimed to identify the epidemiology and characteristics of non-Aspergillus invasive mould infections (NAIMIs).
Proven/probable NAIMIs developed in patients with haematologic diseases were reviewed from January 2011 to August 2018 at Catholic Hematology hospital, Seoul, Korea. There were 689 patients with proven/probable invasive mould infections; of them, 46 (47 isolates) were diagnosed with NAIMIs. Fungi of the Mucorales order (n = 27, 57.4%) were the most common causative fungi, followed by Fusarium (n = 9, 19.1%). Thirty-four patients (73.9%) had neutropenia upon diagnosis of NAIMIs, and 13 (28.3%) were allogeneic stem cell transplantation recipients. The most common site of NAIMIs was the lung (n = 27, 58.7%), followed by disseminated infections (n = 8, 17.4%). There were 23.9% (n = 11) breakthrough IFIs, and 73.9% (n = 34) had co-existing bacterial or viral infections. The overall mortality at 6 and 12 weeks was 30.4% and 39.1%, respectively. Breakthrough IFIs (adjusted hazards ratio [aHR] = 1.99, 95% CI: 1.3-4.41, P = .031) and surgical treatment (aHR = 0.09, 95% CI: 0.02-0.45, P = .003) were independently associated with 6-week overall mortality.
NAIMIs were not rare and occur as a complex form of infection often accompanied by breakthrough/mixed/concurrent IFIs and bacterial or viral infections. More active diagnostic efforts for NAIMIs are needed. 
| INTRODUC TI ON
Invasive fungal infections (IFIs) remain a leading cause of morbidity and mortality in patients with haematologic diseases. 1 Antifungal prophylaxis has already been proven to be clinically effective in preventing IFIs in high-risk patients with haematologic diseases, and primary antifungal prophylaxis (PAP), particularly mould-active azole in high-risk groups is now a standard protocol in international guidelines. 2, 3 These recent advances in the use of PAP during chemotherapy and haematopoietic stem cell transplantation (HSCT) have reduced the number of IFIs and improved the survival of high-risk patients. 4, 5 However, they have also led to changes in the epidemiology of IFIs, and breakthrough IFIs that developed during treatment with mould-active azoles have been reported. [6] [7] [8] [9] Thus, concerns on increasing possibility of rare and more resistant mould infections have been raised, 10 and recent reports have described increasing incidence of non-Aspergillus invasive mould infections (NAIMIs), often in patients receiving mould-active azole drugs. [10] [11] [12] Clinically, it is difficult to distinguish NAIMIs from invasive aspergillosis (IA), and NAIMIs often have a progressive and aggressive course. 10 NAIMIs should be distinguished from IA primarily because many of these non-Aspergillus moulds are not susceptible to or are intrinsically resistant to azoles, including voriconazole. [13] [14] [15] This may lead to treatment failure and increased mortality. However, data for the epidemiology of NAIMIs are limited, owing to its rarity and the lack of microbiological confirmation.
This study aimed to identify the epidemiology, characteristics, and risk factors for mortality of NAIMIs in patients with haematologic diseases and to investigate whether the incidence of NAIMIs has increased since the introduction of PAP.
| PATIENTS AND ME THOD

| Study design
We reviewed the medical records of all adult patients with haematologic diseases who were followed up at Catholic Hematology Hospital from January 2011 to August 2018 and identified all episodes of proven or probable NAIMIs (see "Definitions"). This tertiary hospital performs over 500 HSCTs annually. This study was conducted as part of Catholic Hematology Hospital Fungi Epidemiology 
| Definitions
Definitions of proven/probable NAIMI were applied from the European Organization for Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) definitions of IFIs. 16 Disseminated IFI was defined as involvement of two or more noncontiguous sites or positive blood cultures. 17 Past IFI was defined as a previous IFI over 2 weeks from the end of the treatment.
Breakthrough IFI was defined as (1) occurrence of a proven/probable IFI according to EORTC/MSG definitions while on systemic mouldactive agent PAP or within 14 days after discontinuation of PAP or (2) the appearance of any new lesions indicative of NAIMIs in a patient receiving systemic mould-active agent for at least 14 days with previously diagnosed IFI. 9, 11, 17 Mixed IFI was defined as two or more fungal species identified in the same specimens, 9 while concurrent IFI was defined as two different species identified in non-contiguous sites.
| Microbiologic methods
Moulds were identified primarily via phenotypic studies and morphology and biochemical analysis. Final identification of non-Aspergillus moulds was confirmed via sequencing of internal transcribed spacer (ITS). Their entire ITS regions were amplified using the primers of ITS1-F_KYO2 (5′-TAGAGGAAGTAAAAGTCGTAA-3′) and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′), as previously described. 18 ITS amplicons were sequenced, and then identified using the BLASTN (https ://blast.ncbi.nlm.nih.gov/Blast.cgi).
| Statistical analysis
Differences in qualitative variables between the patients with mucormycosis and those with other NAIMIs were analysed via χ 2 test with continuity correction or Fisherʼs exact test where appropriate.
Meanwhile, differences in quantitative variables were compared via t test. To identify whether the incidence of NAIMIs has increased as year, Spearman correlation analysis was used. A Cox proportional hazards model was applied to identify the independent risk factors of 6-week mortality. A two-tailed P value of ＜0.05 was considered significant. All statistical analyses were performed using SPSS software version 18.0 (SPSS Korea, Seoul, Korea).
| RE SULTS
| Fungal isolates
There were 689 adult patients with proven or probable invasive mould infections (IMIs) during the study period, of which 46 patients (47 isolates; Figure 1 There was no significant increase in the proportion of NAIMIs in total IMIs from January 2011 to August 2018 (correlation coefficient
[rho] = 0.408, P = .364; Figure 2 ). In total, 28 cases (60.8%) met the proven criteria and 18 cases (39.1%) met the probable criteria (Table 1) .
Sixteen cases of NAIMIs were diagnosed via histopathology alone, and all these cases were mucormycosis ( Figure 1 ). Meanwhile, four cases (8.7%) were diagnosed via combined culture and tissue histopathology.
ITS sequencing was performed in 14 of 46 cases (30.4%).
Mucorales (n = 27, 57.4%) was the most common causative fungi, followed by Fusarium (n = 9, 19.1%), Alternaria (n = 2), Scopulariopsis (n = 2), Scedosporium (n = 2), Schizophyllum (n = 2), Paecilomyces (n = 1), Hormographiella (n = 1) and Chaetomium (n = 1). One patient had mixed Mucorales; both Rhizomucor spp. and Lichtheimia spp. were identified in the same sinus tissue culture. Most Mucorales (16 of 27) were confirmed via histopathology alone due to negative culture, and Rhizomucor spp. (n = 5) was the most common species (Figure 1 ).
Of the nine Fusarium isolates, three were F solani, while three others were F dimerum (n = 1), F fujikuroi spp. complex (n = 1) and F verticillioides (n = 1) confirmed via ITS sequencing, the remaining three isolates were unclassified. Of the two Scedosporium, one was S prolificans, while the other was S aurantiacum. Of the two Scopulariopsis, one was S brevicaulis and the other was unclassified. Two Schizophyllum were both S commune and two Alternaria species were unclassified.
The genus Paecilomyces was P variotii; genus Hormographiella, H aspergillata; and genus Chaetomium, C bostrychodes.
| Patient characteristics, sites of infection and comorbidity
The characteristics of patients with NAIMIs are shown in Table 1 .
The median patient age was 52.3 years (±11.2), and 69.6% (n = 32) of the patients were male. In total, 28.3% (n = 13) of NAIMIs occurred in patients with allo-HSCT, and 73.9% (n = 34) had neutropenia upon the diagnosis of NAIMI. There was no statistically significant difference in the rate of patients with neutropenia at the time of diagnosis between the mucormycosis group and other NAIMIs group, but the duration of prediagnosis neutropenia tended to be longer in the other NAIMIs group than that in the mucormycosis group (Table 2 , P = .008). The incidence of proven category was higher in the mucor- 
| Outcomes
The overall mortality at 6 and 12 weeks was 30.4% and 39.1%, respectively. Although there was no statistically significant difference in overall mortality between the mucormycosis group and the other NAIMIs group, 20 of the 26 mucormycosis patients who underwent surgery showed a survival rate of 90.0% at 6 weeks. Six patients died within 6 weeks; of these, 66.7% (4/6) died because they did not undergo surgical treatment due to progression of mucormycosis (mean duration of diagnosis to death = 13.3 days), and 
| D ISCUSS I ON
This cohort study showed the current trend in the epidemiology of NAIMIs before and after the introduction of mould-active azole PAP at a single centre in Korea. NAIMIs accounted for 6.7% of the total IMIs in patients with haematologic diseases during the study period.
The causative fungi of NAIMIs in the patients with haematologic diseases varied. Similar to the findings in other studies, Mucorales was the most common cause of NAIMIs followed by Fusarium spp.. 10, 12, 17 The proportion of NAIMIs in total IMIs did not increase significantly within the study period, but in 2018, seven cases (four of seven are mucormycosis) were already recorded by August, and we expect that the incidence will exceed that in the previous year ( Figure 2) . Therefore, the trend in incidence should be monitored over the next few years to determine whether the incidence of NAIMIs did increase after the introduction of mould-active azole prophylaxis in Korea.
The overall all-cause mortality at 12 weeks was 39.1%, and this was lower than previously reports. 13, 16, 17, 19 There was no significant difference in overall mortality at 6 and 12 weeks between the mucormycosis group and the other NAIMIs group in this study, but the duration of neutropenia before diagnosis more likely longer in the other NAIMIs group. And co-existing infection other than IFIs was more in the other NAIMIs group than mucormycosis group (Table 2) . Although not statistically significant in the multivariate analysis, these factors could be considered as one of reasons for the considerable low rate of surgical treatment in the other NAIMIs group.
Similar to other studies, 17, 20, 21 surgical treatment was an independent predictor of good outcome within 6 weeks on multivariate analysis (aHR = 0.09, 95% CI: 0.02-0.45, P = .003). Surgical treatment of NAIMIs was performed actively in most cases except for those who developed progression of underlying haematologic diseases or was 15%, which is lower than that previously reported as 25%-50%. 20 Therefore, when it is suspected mucormycosis, early aggressive surgical treatment should be performed as soon as possible to reduce mortality.
Another key finding was that NAIMIs are not only single infection; rather, complex forms of infections should be considered.
Ten patients (21.7%) had mixed IFIs, seven patients (15.2%) had concurrent IFIs and 11 patients had breakthrough IFIs (23.9%). Of these, breakthrough IFI is well-known risk factor for mortality in remission induction chemotherapy of AML patients and allo-HSCT recipients. [6] [7] [8] [9] 11, 12, 17, 19 Similarly, multivariate analysis in our study showed that breakthrough IFI is an independent predictor of poor in our data were diagnosed with through the above-mentioned exclusively diagnostic process and included only when treated NAIMI.
But nevertheless, the rate of rare moulds could have been underestimated. Third, some cases did not grow in culture, and thus the antifungal susceptibility test could not be performed in all cases. Fourth, despite of the repetitive efforts to obtain adequate specimens, only specimens with low reliability, such as sputum, were obtained in some patients. These cases were categorised as the probable classification after correlating the host immune status and imaging findings from the EORTC/MSG definitions.
Despite these limitations, this study shows that epidemiology of NAIMIs is not limited to PAP in high-risk patients with haematologic diseases but also shows that NAIMIs were not rare in the clinical setting. Surgical treatment, particularly in suspected cases of mucormycosis, was associated with a significant survival benefit. Mortality 
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